Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HINT1 | P49773 | 4/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945533 | 0.91 | HPGD (0.76) | HPGDIMPDH2IMPDH1PAX8NT5E | |
| SCHEMBL10118075 | 0.91 | HPGD (0.76) | HPGDIMPDH2IMPDH1PAX8NT5E | |
| SCHEMBL16787414 | 0.91 | HPGD (0.76) | HPGDIMPDH2IMPDH1PAX8NT5E | |
| SCHEMBL14440590 | 0.90 | HPGD (0.74) | HPGDIMPDH2IMPDH1PAX8NT5E | |
| SCHEMBL16787416 | 0.90 | HPGD (0.62) | HPGDHINT1IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL19417780 | 0.88 | HINT1 (0.72) | HPGDHINT1IMPDH2IMPDH1NT5E | |
| SCHEMBL784543 | 0.88 | HINT1 (0.72) | HPGDHINT1IMPDH2IMPDH1NT5E | |
| SCHEMBL22268191 | 0.88 | HINT1 (0.72) | HPGDHINT1IMPDH2IMPDH1NT5E | |
| SCHEMBL14559271 | 0.88 | HINT1 (0.72) | HPGDHINT1IMPDH2IMPDH1NT5E | |
| SCHEMBL19204426 | 0.88 | HINT1 (0.72) | HPGDHINT1IMPDH2IMPDH1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261166-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | ALNYLAM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20110027882-A1 | Methods and Compositions for Treating Neurological Disease | UNIVERSITY OF MASSACHUSETTS | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261166-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | HPGD 3859/4885HINT1 3049/4885IMPDH2 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.